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The G-protein coupled receptor associated protein
-arrestin-1 is crucial for the regulation of numer-
ous biological processes involved in cancer pro-
gression, such as intracellular signaling and cell
motility. The encoding gene ARRB1 is harbored in
the same chromosomal region as the CCND1 gene
(11q13). Amplification of CCND1, frequently en-
countered in breast cancer, often involves coampli-
fication of additional oncogenes, as well as deletion
of distal 11q genes. We investigated the clinical rel-
evance of -arrestin-1 in breast cancer and eluci-
dated a potential link between -arrestin-1 expres-
sion and CCND1 amplification. -Arrestin-1 protein
expression was evaluated in two breast cancer pa-
tient cohorts, comprising 179 patients (cohort I)
and 500 patients randomized to either tamoxifen or
no adjuvant treatment (cohort II). Additionally, mi-
gration after -arrestin-1 overexpression or silenc-
ing was monitored in two breast cancer cell lines.
Overexpression of -arrestin-1 reduced the migra-
tory propensity of both cell lines, whereas silencing
increased migration. In cohort I, high expression of
stromal -arrestin-1 was linked to reduced patient
survival, whereas in cohort II both high and absent
stromal expression predicted a poor clinical out-
come. Patients exhibiting low or moderate levels of
stromal -arrestin-1 did not benefit from tamox-
ifen, in contrast to patients exhibiting absent or
high expression. Furthermore, CCND1 amplifica-
tion was inversely correlated with tumor cell ex-
pression of -arrestin-1, indicating ARRB1 gene de-
340letion in CCND1-amplified breast cancers. (J Mol
Diagn 2011, 13:340–351; DOI: 10.1016/j.jmoldx.2011.01.009)
-arrestin-1 belongs to a small family comprised of four
members, designated arrestin 1 to 4. Arrestins 1 and 4
are exclusively expressed in retinal photoreceptors, but
arrestins 2 and 3 (termed -arrestin-1 and -2, respec-
tively) are expressed in virtually all tissues.1 After their
activation and phosphorylation by G-protein-coupled re-
ceptor kinases,2 the versatile -arrestin adaptor proteins
function in regulation of signaling and trafficking of G-pro-
tein-coupled receptors. The binding of -arrestin steri-
cally prevents further G-protein signaling and hence de-
sensitizes the receptor.3 In recent years, the novel role of
-arrestins in signaling has been extensively studied, and
their function as scaffold proteins interacting with a num-
ber of different signaling molecules has emerged.1,4,5 Of
note, as G-protein signaling is turned off, a second set of
signals can be initiated. Signaling pathways reported to
be modulated by -arrestins include the TGF-, IGF-1R,
PI3K, and MAPK pathways.2,6
A number of studies have investigated the role of the
-arrestins in cancer. In colorectal cancer, the interaction
between -arrestin-1 and proto-oncogene SRC (alias c-Src)
has been shown to be critical for cell migration in vitro and
also for metastatic spread to the liver in vivo.7 Zou et al6
demonstrated that murine liver cancer and lymphoma cells
inoculated into -arrestin-1 transgenic mice formed tumors
more rapidly than in either -arrestin-2 transgenic or wild-
type mice. Furthermore, migration of the invasive breast
cancer cell line MDA-MB-231 has been shown to be re-
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has also been implicated in cell death in MCF-7 and MDA-
MB-231 cells, by blocking morphine-induced cell death
through proapoptotic caspase-8 pathways.10 In a study
analyzing expression of the -arrestins in 48 breast cancer
samples, mRNA levels of -arrestin-2 were elevated in ad-
vanced breast cancers.9 To date, however, no previous
studies have described the importance of -arrestin-1 pro-
tein expression in a clinical setting and including analysis of
a large number of breast cancer cases.
The ARRB1 gene coding for the -arrestin-1 protein
maps to chromosomal locus 11q13,11 a region that is fre-
quently amplified in certain human cancers, including lung,
bladder, breast, and ovarian carcinomas.2,7,12 The well-
characterized gene CCND1 is also harbored in the 11q13
region, and its amplification has been associated with
worse clinical outcome in several cancers.13,14 Jirström
et al15 reported that patients with CCND1-amplified breast
cancers were subject to an increased risk of disease recur-
rence after treatment with the selective estrogen receptor
modulator tamoxifen, compared with patients with nonam-
plified tumors. PAK1, another gene located at 11q13, has
been reported to be coamplified with CCND1,16 and over-
expression of PAK1 protein is associated with impaired
tamoxifen response in premenopausal breast cancer pa-
tients, despite the presence of estrogen receptor (ER)
expression.17 The ARRB1 gene is located between the
CCND1 and the PAK1 genes, suggesting that a coamplifi-
cation of these two genesmay also include ARRB1.18 More-
over, loss of heterozygosity at the distal region of chromo-
some 11q, including genes such as CHEK1 (alias CHK1)
(11q24), has also been associated with 11q13 amplifica-
tion.19 We have previously reported loss of CHEK1 protein
to be a predictor of tamoxifen response in premenopausal
breast cancer, abolishing the response seen in patie-
nts presenting with tumors that exhibit normal levels of
CHEK1.20 Based on these data, we hypothesized that
ARRB1 may be a candidate gene affected by the amplifi-
cation/deletion event occurring at chromosome 11q. Fur-
thermore, -arrestin-1 may also be a relevant predictor of
response to tamoxifen treatment, given the involvement of
cyclin D1, PAK1, and CHEK1 in breast cancer.
Recently, a comprehensive atlas of human protein ex-
pression patterns was generated through the Human Pro-
tein Atlas program (http://www.proteinatlas.org; last ac-
cessed March 13, 2010).21,22 At present,3000 antibodies
(corresponding to 2600 different human proteins) have
been screened in TMAs, representing 48 types of normal
tissues, the 20 most common forms of human cancer, and
47 cell lines, using an antibody-based proteomics strat-
egy.23 Notably, the Human Protein Atlas can also be used as
a platform for in silico discovery of new cancer biomark-
ers.24–26 In this fashion, we ventured to perform a systematic
screeningof 11q13geneproducts and found that-arrestin-1,
although sparsely expressed in normal breast tissue, exhibited
a differential expression ranging from negative to high among
breast cancers. Notably, no other forms of cancer displayed a
high expression of this protein.
To assess the importance of -arrestin-1 in breast can-
cer, TMAs with tumor samples from two independent
breast cancer cohorts were analyzed and, based on theinitial evaluation, the relevance for both tumor and stro-
mal cell protein expression was investigated. A possible
link between ARRB1 and CCND1 amplification was also
elucidated, by studying -arrestin-1 protein expression in
relation to amplification status of CCND1, analyzed by
fluorescence in situ hybridization. Of note, stromal -ar-
restin-1, irrespective of tumor cell expression, was shown
to be a critical prognostic marker in both cohorts. Fur-
thermore, patients exhibiting low or moderate stromal
-arrestin-1 expression did not benefit from treatment
with tamoxifen, whereas those showing negative or high
stromal expression responded well. Finally, a link be-
tween -arrestin-1 protein expression and CCND1 ampli-
fication was observed in the larger cohort. To our knowl-
edge, this is the first study demonstrating the potential
importance of -arrestin-1 as a prognostic and treatment
predictive marker in breast cancer.
Materials and Methods
Cell Lines, Western Blot, and
Immunocytochemistry
The human breast cancer cell lines MDA-MB-468 and
MDA-MB-231 (ATCC, Manassas, VA) were used to verify
the reactivity of the -arrestin-1 antibody [rabbit monoclonal
against human -arrestin-1 (1:200, E246; Epitomics, Burlin-
game, CA)], by immunocytochemistry. For detailed de-
scription of culturing conditions, immunocytochemistry, and
Western blot, we refer to a previous report.27 For detection
of -arrestin-1 overexpression, rabbit polyclonal anti-GFP
antibody (1:1000, sc-8334; Santa Cruz, Biotechnology,
Santa Cruz, CA) was used. To monitor cell proliferation,
rabbit polyclonal anti-human cyclin A (1:500, H-432, sc-751,
Santa Cruz, Biotechnology, Santa Cruz, CA) was used;
for apoptosis detection, rabbit polyclonal anti-human
caspase-3 antibody (1:500, P42574; Cell Signaling Tech-
nology, Danvers, MA) was used.
Transfection
For transient expression of wild-type -arrestin-1, we used
the pcDNA3 expression plasmid encoding EGFP--arres-
tin-1,28 kindly provided by Dr. Vsevolod V. Gurevich (Van-
derbilt University, Nashville, TN). For transfection in six-well
plates, MDA-MB-468 and MDA-MB-231 were transiently
transfected with -arrestin-1 vector using Lipofectamine
2000 according to the manufacturer’s recommendations
(Invitrogen Life Technologies, Carlsbad, CA). Two micro-
grams DNA was used per well of a six-well plate. For -ar-
restin-1 knockdown, MDA-MB-468 and MDA-MB-231 cells
were transfected with 50 nmol/L control small interfering
RNA (siRNA) or siRNA against -arrestin-1 (ON-TARGET-
plus siRNA, SMARTpool) using Dharmafect (both from
Dharmacon, Lafayette, CO). Cells were allowed to grow for
48 hours after transfection before being harvested for mi-
gration assay. Cell pellets were made from control and
-arrestin-1 transfected cells 48 hours after transfection,
and an immunocytochemistry array was constructed and
stained with -arrestin-1 antibody.
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Migration assays were performed in Transwell migration
chambers with 8-m pore membranes (Corning, Corn-
ing, NY). Cells (105) were resuspended in upper Trans-
well chambers in serum-free media and were allowed to
migrate toward a serum gradient (10%) in the lower
chamber for 3 hours (MDA-MB-231) or 6 hours (MDA-
MB-468). Membranes were then excised, and cells on
the upper side were removed before fixation in 4% para-
formaldehyde and staining with DAPI prior to mounting.
The number of migrating cells was counted in three ran-
domly chosen fields on each membrane, photographed
at 10 magnification. Values reported are the averages
of three experiments performed in triplicate.
Patients
Cohort I
Designed as a first-line screening cohort for Human
Protein Atlas antibodies with potential relevance in breast
cancer, cohort I comprises 179 patients diagnosed with
primary invasive breast cancer between 2000 and 2002
at the Department of Pathology, Malmö University Hospi-
tal. Median age at diagnosis was 65 years (range, 35 to
97 years), and median follow-up time was 69 months. All
patients in cohort I had been treated after surgery. For
detailed description of clinicopathological features of the
tumor samples, we refer to previous studies.29,30 Ethical
permission for the study was obtained from the Ethics
Committee at Lund University (ref 445/2007), whereby
informed consent was deemed not to be required other
than by the opt-out method.
Cohort II
Cohort II was established from a previous clinical trial
population. Between 1986 and 1991, 564 premenopausal
breast cancer patients with invasive stage II disease
were enrolled in a Swedish trial (SBII:2a) in which they
were randomized to receive either 2 years of adjuvant
tamoxifen (n 276) or no adjuvant treatment (control, n
288). All patients were followed for recurrence-free and
overall survival. Recurrence was defined as local, re-
gional, or distant recurrence or breast cancer-specific
death; contralateral breast cancer was excluded. Each
patient received surgery (either modified radical mas-
tectomy or breast-conserving surgery), followed by ra-
diotherapy and in few cases (2%) by adjuvant poly-
chemotherapy. After surgery, the median follow-up
time without breast cancer event was 13.9 years. De-
tailed description of the SBII:2a study design is avail-
able in a previous report.31 Informed consent was
obtained from the patients participating in the random-
ized study, and the ethical committees at Lund and
Linköping Universities approved the study and the re-
analysis of the tumor material.Tissue Specimens and Immunohistochemistry
FFPE tumor material was available from 500 of the 564
patients in cohort II. Areas representative of invasive
cancer were selected and assembled in a TMA. Two
tissue cores (cohort I, 1.0 mm; cohort II, 0.6 mm) from
each donor block were placed in recipient paraffin
block by using an automated tissue arrayer (Beecher
Instruments Microarray Technology, Woodland, MD).
Sections (4 m) from this block were mounted onto
slides before being deparaffinized, rehydrated. and
microwave-treated in target retrieval solution pH 9.9
(Dako, Glostrup, Denmark) and then processed in an
automated immunostainer (Techmate 500; Dako, Co-
penhagen, Denmark), using Envision software version
3.0 (Dako, Glostrup). The -arrestin-1 antibody was
diluted 1:200 also for IHC. Because -arrestin-1 was
expressed in various intensities both in the cytoplasm
of the tumor cells and in the surrounding stromal cells,
staining intensity of both compartments was evaluated
and was scored as follows: 0  negative, 1  low, 2 
moderate, or 3  high. Evaluation was performed in-
dependently by two different observers (K.L. and G.L.).
Conflicting observations were low (5%) for all evalu-
ations made. All immunohistochemical evaluations
were performed without knowledge of tumor character-
istics. In cases of no evaluation, the tumor cores were
either nonrepresentative (ie, contained no invasive tu-
mor cells) or missing.
Expression of carbonic anhydrase 9 (CAIX) and vimen-
tin had previously been assessed in cohort I (unpub-
lished data). CAIX staining was assessed as negative or
positive and stromal staining intensity for vimentin was
graded from 0 to 3. In cohort II, data for expression of
ER and progesterone receptor (PR),32 as well as ampli-
fication status of ERBB2 (alias HER2),33 were available
from previous studies.32,33 When performing survival
analyses in which treatment response between different
subgroups was compared, only ER-positive tumors
were analyzed (cutoff at 10% positively stained nuclei
according to Swedish clinical protocols). We selected
ER-positive patients for the analyses, because this sub-
group of patients can be regarded as potential respond-
ers to ER-targeting therapy, such as tamoxifen. Staining
of the proliferation marker Ki-6732 (not available for cohort
I) and HIF-134 in cohort II had also been performed
previously. Data regarding CCND1 gene amplification
status (assessed by fluorescence in situ hybridization
analysis)15 and protein expression data for CHEK120 and
stromal -smooth muscle actin (-SMA) (scored 0 to 3,
negative to high) were also available.15,20
Statistical Methods
Statistical analyses were performed using SPSS software
version 15.0 (SPSS, Chicago, IL). For examination of
the statistical significance of associations between -
arrestin-1 expression and other categorical variables,
Spearman’s rank-order correlation coefficient and Wil-
coxon-Mann-Whitney U-tests were used. To study recur-
rence-free survival (RFS), the Kaplan-Meier method was
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the log-rank test was used. A Cox proportional hazards
regression model was used for relative risk estimation in
multivariate analysis. All hazard ratios have been ad-
justed for age (continuous), Nottingham histological
grade (NHG; I/II versus III), lymph node status (negative
versus positive), and for cohort II also for Ki-67 nuclear
fraction (0% to1%, 2% to 10%, 11% to 25%, 26% to 50%,
and 51% to 100%); data for Ki-67 were not available for
cohort I. We evaluated whether the effect of tamoxifen
treatment was modified by stromal -arrestin-1 by adding
an interaction term to the Cox regression model. All P
values corresponded to two-sided tests and a P value of
0.05 was considered statistically significant. This study
was conducted according to the guidelines provided by
the REMARK study.35
Results
-Arrestin-1 Expression Affects Breast Cancer
Cell Migration
-Arrestin-1 antibody reactivity was first tested by siRNA
silencing of -arrestin-1 in MDA-MB-468 and MDA-MB-
231 breast cancer cells. Significantly decreased levels of
the protein were detected by immunocytochemistry for
-arrestin-1 siRNA transfected cells, compared with con-
trol, 48 hours after transfection (Figure 1B). In parallel
with the immunohistochemical validation of the antibody,
we tested the migratory capacity of MDA-MB-468 and
MDA-MB-231 cells after overexpression and silencing of
-arrestin-1. Overexpression was detected with anti-GFP
antibody using Western blot analysis (Figure 1A). Of note,
-arrestin-1 overexpression significantly reduced the mi-
gratory propensity of both cell lines 48 hours after trans-
fection (Figure 1C), whereas silencing resulted in prom-
inently increased migration (Figure 1D). To exclude the
possibility that decreased migration was an effect of re-
duced cell viability due to vector transfection, we used
Western blot analysis to monitor proliferation and apop-
tosis in both cell lines 48 hours after vector transfection.
No change in proliferation or increased apoptosis was
observed in cells overexpressing -arrestin-1, compared
with control transfected cells, indicating that the de-
creased migration observed was a true effect of -arres-
tin-1 overexpression (see Supplemental Figure S1 at
http://jmd.amjpathol.org).
-Arrestin-1 Is Expressed in both Tumor Cells
and Stroma of Primary Breast Tumors
Based on the discovery that overexpression of -arres-
tin-1 expression was restricted exclusively to breast
cancers in the Human Protein Atlas, we further inves-
tigated its protein expression in two independent co-
horts of breast cancer cases. -Arrestin-1 protein ex-
pression was first evaluated in cohort I, consisting of a
TMA of 179 breast tumors. Notably, apart from the
expected cytoplasmic tumor cell expression, -arres-
tin-1 was also detectable in stromal cells, includingfibroblasts, endothelial cells, and various immune
cells. To validate the staining of the TMAs, normal
breast tissue was also stained for IHC. Expression of
-arrestin-1 was observed exclusively in endothelial
and luminal epithelial cells in normal breast tissue; no
staining of the stromal compartment was detected.
Both tumor cell and stromal staining of the breast can-
cer samples varied greatly, from no staining at all to
very intense staining. From this point onwards, stromal
staining intensity was assessed separately from the
tumor cell staining intensity (Figure 2). In cohort I,
tumor cell staining of -arrestin-1 was assessable in
131/179 tumors and stromal staining in 130/179 tu-
mors. Next, we validated our findings in cohort II (the
larger cohort, consisting of 500 tumors); and 359/500
tumors were assessable for both tumor cell and stromal
Figure 1. -Arrestin-1 antibody validation and migratory propensity of
breast cancer cells (MDA-MB-468 and MDA-MB-231 cell lines) after -arres-
tin-1 overexpression and silencing. A: -Arrestin-1 overexpression was de-
tected with anti-GFP antibody on Western blot, 48 hours after transfection. V,
vector. B: Protein expression was significantly decreased 48 hours after
transfection with siRNA against -arrestin-1 in both cell lines, analyzed by
immunocytochemistry. Magnification 40. C: Overexpression of -arrestin-1
reduced migration of both cell lines, compared with control, 48 hours after
transfection. *P  0.001; **P  0.001. D: Knockdown of -arrestin-1 resulted
in an increased migratory propensity of both cell lines, compared with
control, 48 hours after transfection. *P  0.001; **P  0.001.staining.
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Is Associated with Different Tumor
Characteristics
First, we wanted to elucidate possible associations between
the expression of -arrestin-1 and clinicopathological pa-
rameters, as well as other markers for tumor behavior. In
cohort I, tumor cell expression of -arrestin-1 was inversely
correlated with ER expression (P  0.028) and positively
correlated with ERBB2 amplification status (P  0.001) and
age (P 0.006), whereas stromal expression was inversely
correlated with ER expression (P  0.001) and positively
correlated with ERBB2 status (P 0.042), NHG (P 0.017),
tumor size (P  0.029), lymph node status (P  0.014),
distant metastases (P 0.004), and expression of the hyp-
oxia marker CAIX (P  0.027) (Table 1). A positive correla-
tion between tumor cell and stromal expression of -arres-
tin-1 was also observed (P  0.001). These contrasting
associations between relevant clinicopathological variables
and tumor cell versus stromal -arrestin-1 expression imply
distinct roles for this protein in different cellular compart-
ments of a tumor.
The associations of -arrestin-1 to prognostic markers
found in cohort I were analyzed in cohort II with consis-
tent results. In cohort II, comprising 500 premenopausal
breast cancer cases, the expression of tumor cell -ar-
restin-1 was inversely correlated with ER expression
(P  0.015) and PR expression (P  0.002) (Table 2).
Notably, in contrast to cohort I, tumor cell -arrestin-1
expression was inversely correlated with age (P 0.003).
In addition, tumor cell expression was positively corre-
lated with ERBB2 status (P  0.003) and NHG (P 
0.003) (Table 2). Stromal expression of -arrestin-1 was
inversely correlated with ER (P 0.006) and PR expres-
sion (P  0.001) and was positively correlated with NHG
(P  0.001), tumor size (P  0.038), proliferation (Ki-67)
(P  0.001), and hypoxia inducible factor-1 (HIF-1)
Figure 2. Immunohistochemical staining of -arrestin-1 in primary breast
tumors. Cytoplasmic tumor cell -arrestin-1 expression was evaluated as
negative (A), low (B), moderate (C), or high (D). Stromal expression (Neg-
High) was observed to be high (B) in some tumors in which tumor cell
expression was quite low, and the opposite was also observed: low (D),
when tumor cell expression was high. Scale bar applies to all images.expression (P  0.024) (Table 2). As for cohort I, a pos-itive correlation was observed between tumor cell and
stromal -arrestin-1 expression in cohort II (P  0.001).
-Arrestin-1 Is A Prognostic and Treatment
Predictive Marker in Breast Cancer
To investigate the influence of -arrestin-1 expression on
disease outcome, we studied patient survival according
to tumor cell or stromal -arrestin-1 expression. Although
tumor cell expression did not affect RFS in cohort I
(Figure 3A), patients with tumors exhibiting high levels of
stromal -arrestin-1 were subject to a shorter RFS than
were those with tumors of lower expression levels (P 
0.001) (Figure 3A). Notably, multivariate Cox regression
analysis revealed an independent prognostic value for
stromal -arrestin-1 expression in cohort I (hazard ratio
HR  2.72, 95% confidence interval CI  1.06 to 6.98;
P  0.038) (Table 3). To exclude the possibility that
stromal -arrestin-1 was associated with worse prognosis
because its expression was dependent on the amount of
stromal tissue in the tumor, we analyzed the link to the
mesenchymal cell marker protein vimentin, abundantly
expressed by fibroblasts. A positive correlation between
stromal -arrestin-1 and vimentin was observed in cohort
I, but vimentin did not reveal any independent prognostic
information, implying a specific role for -arrestin-1, irre-
spective of tumor stroma, for clinical outcome in breast
cancer (data not shown).
In cohort II, RFS in the subgroup of untreated control
patients was analyzed first, to avoid the potential bias of
treatment influencing the results. Only a trend indicating
a shorter RFS in patients with tumors of high tumor cell
-arrestin-1 expression was observed (Figure 3B). In
contrast to cohort I, both negative and high stromal -ar-
restin-1 expression were associated with a reduced RFS,
compared with low or moderate expression (P  0.010)
(Figure 3B). Because the curves for patients with tumors
of negative and high stromal -arrestin-1 expression
overlapped and were associated with a shorter RFS com-
pared with patients with tumors of low or moderate ex-
pression, patients were divided into two subgroups (neg-
ative or high versus low or moderate) for the multivariate
Cox regression analysis. Notably, -arrestin-1 expression
was an independent prognostic factor (HR  0.44, 95%
CI 0.25 to 0.79; P 0.006) in cohort II as well (Table 4).
Expression of stromal -arrestin-1 was positively corre-
lated with stromal -SMA, a marker for carcinoma-asso-
ciated fibroblasts (P  0.009); however, expression of
-SMA was not associated with recurrence rate.
Because several gene products of chromosomal region
11q have been reported to be associated with impaired
tamoxifen response, we wanted to further delineate the ef-
fect of -arrestin-1 expression on response to this selective
estrogen receptor modulator. Cohort II is based on a large
clinical trial including breast cancer patients randomly as-
signed to either 2 years of tamoxifen treatment or to no
adjuvant treatment. Tumor cell expression of -arrestin-1
had no effect on tamoxifen response in the subgroup of
ER-positive patients selected for these analyses (data not
shown). Furthermore, no effect on treatment response was
pecified
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were not subcategorized (data not shown). However, when
analyzing the difference in tamoxifen response according to
stromal expression subcategorized as negative or high
versus low or moderate, based on previous survival
analyses, an intriguing feature was observed: RFS
among patients who presented with tumors of negative
or high -arrestin-1 expression was improved with ta-
moxifen (P  0.002), in contrast to patients exhibiting
low or moderate expression (P  0.128) (Figure 3C). A
multivariate Cox proportional hazard regression model
for stromal -arrestin-1 and treatment interaction re-
vealed a statistically significant difference between the
two subgroups defined as negative or high versus low
Table 1. Distribution of -Arrestin-1 Staining Category According
Variable
-Arrestin-1
Tumor cell staining intensity
0 1 2
Sample size n  56 n  58 n  14 n
Sample % of total 42.7 44.3 10.7
ER positive (%)
10 3 5 5
10 52 52 9
Missing cases: 48/49
PR positive (%)
10 14 19 6
10 42 39 8
Missing cases: 48/49
ERBB2 status
Negative 43 31 5
1 9 14 3
2 2 9 2
3 2 4 4
Missing cases: 48/49
NHG
I 9 8 4
II 26 28 2
III 21 22 8
Missing cases: 48/49
Tumor size
20 28 34 6
20 28 24 8
Missing cases: 48/49
Lymph node status
N0 31 27 8
N1–3 15 15 2
N4 7 8 3
Missing cases: 61/62
Distant metastases
No 51 51 13
Yes 5 7 1
Missing cases: 48/49
CAIX
Negative 45 39 6
Positive 3 5 3
Missing cases: 77/78
Age at surgery (yr)
Median 61 72 72 6
Range 40–89 35–97 42–81 64
Missing cases: 48/49
CAIX, carbonic anhydrase IX; ER, estrogen receptor; ERBB2, epiderm
receptor.
*Correlations were calculated using Spearman’s  unless otherwise s
†Wilcoxon/Mann-Whitney test (two-sided).or moderate (HR  5.31, 95% CI  1.34 to 20.96; P 0.017) (Table 5). These results indicate that patients
exhibiting low or moderate stromal -arrestin-1 expres-
sion are less likely to respond to tamoxifen, compared
with patients exhibiting negative or high expression.
-Arrestin-1 Expression Is Inversely Correlated
with Amplification of CCND1 and Positively
Correlated with CHEK1 Expression
Given that both CCND1 and the ARRB1 gene map to the
chromosomal amplification region 11q13, our next objec-
tive was to investigate a possible link between -arres-
tin-1 expression and amplification of CCND1. Unfortu-
nicopathological Parameters and Tumor Markers in Cohort I
P*
-Arrestin-1
P*
Stromal staining intensity
0 1 2 3
n  13 n  57 n  54 n  6
10.0 43.8 41.5 4.6
0.028† 0.001†
0 2 8 3
13 53 46 3
0.325† 0.430†
4 15 15 4
9 42 39 2
0.001 0.042
10 36 33 1
1 16 8 2
1 3 8 1
1 2 5 2
0.879 0.017
2 14 7 0
6 27 24 0
5 16 23 6
0.485† 0.029†
10 34 24 3
3 23 30 3
0.952 0.014
12 28 26 1
0 16 15 1
1 6 8 3
0.970† 0.004†
13 54 47 3
0 3 7 3
0.072† 0.027†
10 36 41 3
0 3 5 3
0.006 0.126
63 65 65 78
47–82 35–92 35–97 40–81
th factor receptor; NHG, Nottingham histologic grade; PR, progesterone
.to Cli
3
 3
2.3
0
3
0
3
2
1
0
0
2
1
0
3
0
2
0
0
3
0
1
0
6
–83
al grownately, no data for ARRB1 gene expression were
pecified
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-arrestin-1 expression was inversely correlated with am-
plification of CCND1 (P  0.041) (Table 2) in cohort II (no
Table 2. Distribution of -Arrestin-1 Staining Category According
Variable
-Arrestin-1
Tumor cell staining intensity
0 1 2
Sample size n  27 n  202 n  110 n
Sample % of total 7.5 56.3 30.6
ER positive (%)
10 6 55 41
10 21 140 63
Missing cases: 155
PR positive (%)
10 5 51 43
10 20 135 62
Missing cases: 166
ERBB2 status
Nonamplified 18 137 69
Amplified 1 13 13
Missing cases: 232
NHG
I 2 28 6
II 13 96 42
III 12 73 54
Missing cases: 154
Tumor size, mm
20 10 75 41
20 17 127 68
Missing cases: 142
Lymph node status
N0 7 49 35
N1–3 18 108 47
N4 2 43 28
Missing cases: 141
Distant metastases
No 12 118 57
Yes 15 84 53
Missing cases: 141
Ki67 positive (%)
0–10 14 84 39
11–25 7 45 30
26–100 4 49 25
Missing cases: 184
CCND1 status
Nonamplified 12 98 55
Amplified 5 20 8
Missing cases: 289
CHEK1 positive nuclei
(%)
0–5 6 52 23
6–50 14 74 48
51–100 0 15 12
Missing cases: 240
HIF-1 positive (%)
0–1 17 116 61
2–10 2 23 16
11–100 3 12 9
Missing cases: 223
Age at surgery (yr)
Median 45 46 43
Range 35–50 29–57 26–55
Missing cases: 141
CHEK1, checkpoint kinase 1; ER, estrogen receptor; ERBB2, epide
histologic grade; PR, progesterone receptor.
*Correlations were calculated using Spearman’s  unless otherwise s
†Wilcoxon/Mann-Whitney test (two-sided).data for CCND1 amplification were available for cohort I).Furthermore, in cohort II both tumor cell and stromal
expression of -arrestin-1 was positively correlated with
expression of CHEK1 (alias CHK1), a marker for 11q
nicopathological Parameters and Tumor Markers in Cohort II
P*
-Arrestin-1
P*
Stromal staining intensity
0 1 2 3
n  30 n  168 n  140 n  21
8.4 46.8 39.0 5.8
0.015† 0.006†
7 42 47 14
19 117 92 7
0.002† 0.001†
5 40 51 12
19 115 85 7
0.003† 0.370†
17 107 96 15
0 16 14 3
0.003 0.001
3 25 10 1
16 79 53 5
11 58 71 14
0.988† 0.038†
15 67 44 7
15 100 96 14
0.703 6 42 40 9 0.188
18 86 76 5
6 39 23 7
0.632† 0.496†
14 92 80 11
16 76 60 10
0.097 0.001
17 80 43 4
4 40 36 5
2 27 47 11
0.041† 0.429†
12 87 66 13
4 15 14 0
0.030 0.001
9 47 26 3
9 56 67 10
0 10 18 5
0.388 0.024
18 100 77 12
1 15 26 3
2 9 14 0
0.003 0.903
44 45 45 42
30–51 29–57 26–57 39–5
owth factor receptor; HIF, hypoxia inducible factor; NHG, Nottingham
.to Cli
3
 20
5.6
8
11
9
9
11
6
3
2
15
7
13
6
12
2
10
10
7
3
9
13
0
4
6
6
13
4
1
45
37–5
rmal grdeletion (tumor cell, P 0.030; stroma, P 0.001) (Table
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expression in tumor cells was inversely correlated with
CCND1 amplification in the same patient cohort,20 imply-
ing that the CHEK1 gene is deleted concurrently with
amplification of 11q13. These observations suggest an
inverse relationship between the CCND1 and the ARRB1
genes, and thus ARRB1 might be deleted instead of
being coamplified with CCND1, despite the close prox-
imity of the two genes.
Discussion
The role of -arrestin-1 in breast cancer has not been ex-
tensively studied, and in particular its clinical relevance has
not previously been addressed. By analyzing two different
cohorts, one including a subset of both pre- and postmeno-
pausal breast cancer patients and another including pre-
menopausal patients randomized to either 2 years of adju-
vant tamoxifen or no adjuvant treatment, we had the
opportunity to validate the significance of -arrestin-1 pro-
tein expression in relation to patient outcome. Partial agree-
ment between the observations made in the different co-
Table 3. Recurrence-Free Survival with Cox Multivariate
Analysis for Patients in Cohort I
Variable
Multivariate HR
(95% CI) P
-arrestin-1 stroma 0.038
Low, 0–1 1.00
High, 2–3 2.72 (1.06–6.98)
NHG 0.019
I–II 1.00
III 2.81 (1.18–6.70)
Lymph node status 0.001
N0 1.00
N 1.18 (1.09–1.29)
Age 0.110
Continuous (per year) 1.03 (0.99–1.06)CI, Confidence interval; HR, hazard ratio; NHG, Nottingham histologic
grade.horts suggests an important role for -arrestin-1 protein in
the context of tumor behavior. The positive correlations be-
tween stromal -arrestin-1 expression and clinicopatholog-
ical markers such as NHG, tumor size, node status (cohort
I), and proliferation (cohort II) suggests that -arrestin-1 is a
negative predictor of outcome. However, in cohort II, both
high expression and absent expression of -arrestin-1 was
associated with a poor clinical outcome. The present find-
ings demonstrate that both loss and elevated expression of
-arrestin-1 in the stromal compartment of breast tumors
are associated with poor prognosis, independent of stan-
dard clinicopathological risk factors.
In contrast to previous reports for MDA-MB-231 breast
cancer cells,8,9 migration of both MDA-MB-468 and
MDA-MB-231 cells was increased when -arrestin-1 was
silenced. In accordance with these results, overexpres-
sion of the protein decreased migration, implying that
-arrestin-1 is a negative regulator of migration in these
breast cancer cell lines. In previous studies, however,
migration was induced by either protease-activated re-
Figure 3. Kaplan-Meier curves showing the effect of -arrestin-1 on RFS.
A: In cohort I, only stromal expression (right panel) had an effect on
overall survival. B: In the subgroup of untreated control patients of cohort
II, negative or high expression of stromal -arrestin-1 was associated with
a shorter RFS, compared with low or moderate expression (right panel).
There was a trend indicating that also high tumor cell expression was linked
to a reduced RFS in cohort II (left panel). C: ER-positive patients with
tumors of low or moderate stromal -arrestin-1 expression (right panel)
did not benefit from tamoxifen treatment, in contrast to patients with tumors
exhibiting negative or high expression (left panel).
Table 4. Recurrence-Free Survival with Cox Multivariate
Analysis for Patients in Cohort II
Variable
Multivariate HR
(95% CI) P
-arrestin-1 stroma 0.006
Negative or high 1.00
Low or moderate 0.44 (0.250.79)
NHG 0.038
I–II 1.00
III 1.62 (1.03–2.55)
Lymph node status 0.030
N0 1.00
N 1.88 (1.06–3.34)
Age 0.165
Continuous (per year) 0.97 (0.94–1.01)
Ki67 positive (%) 0.923
25 1.00
25 1.03 (0.61–1.73)CI, Confidence interval; HR, hazard ratio; NHG, Nottingham histologic
grade.
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whereas we monitored migration toward serum without
additional stimulating agents in uncoated wells, which
might explain the conflicting results. Notably, tumor cell
expression of -arrestin-1 was not the crucial factor de-
termining tumor aggressiveness in our patient cohorts.
Instead, lymph node status and distant metastases (two
features that define the capability of cells to migrate)
were related to the expression of stromal -arrestin-1.
In recent years, a wealth of data regarding the influ-
ence of the tumor microenvironment in breast cancer has
stimulated new ideas about the mechanism for develop-
ment and progression of the disease.36–38 Communica-
tion between tumor cells and the surrounding cells is
central to these hypotheses.39 The present study ad-
dressed -arrestin-1, a protein prominent for the commu-
nication between different cell types, via G-protein-cou-
pled receptors, and whose expression levels have here
been shown to have important effects on tumor progres-
sion. The actual role of -arrestin-1 expression by stromal
cells is unclear, and the specific cell types expressing
this protein have not yet been identified. Nonetheless, in
our tumor materials, fibroblasts, endothelial cells and im-
mune cells all displayed -arrestin-1 staining of varying
intensities. Our results suggest that stromal expression is
indicative of the clinical outcome independent of tumor
cell expression. Notably, in staining of normal breast tis-
sue the appearance of -arrestin-1 was strikingly differ-
ent, compared with tumor tissue, with only weak staining
of endothelial cells and normal luminal epithelial cells and
without staining of the stroma. Studies are needed to
investigate the effect of -arrestin-1 in stromal cells in
vitro, and also to elucidate the effect of altered protein
expression in fibroblasts on breast cancer cells (to clarify
its importance for paracrine signaling). Unfortunately,
such experiments were beyond the scope of this clini-
cally oriented study.
As already noted, cancer cells have the ability to alter
Table 5. Recurrence-Free Survival with Cox Multivariate
Analysis According to -Arrestin-1 Expression and
Treatment Interaction for Patients in Cohort II
ER positive
(n  384)*
Multivariate HR
(95% CI) P
-arrestin-1 stroma 0.001
Negative or high 1.00
Low or moderate 0.27 (0.130.55)†
Treatment 0.001
Control 1.00
Tamoxifen 0.12 (0.030.44)‡
Interaction variable§ 0.017
Value 5.31 (1.34–20.96)
CI, Confidence interval; HR, hazard ratio; NHG, Nottingham histologic
grade.
*Other factors included in the multivariate analysis: age (continuous),
tumor grade (NHG III versus III), proliferation (Ki67 0–1, 2–10, 11–25,
26–50, 51–100%), and nodal status (negative versus positive).
†Stromal -arrestin-1 hazard ratio for the control group.
‡Treatment hazard ratio for the stromal -arrestin-1 subgroup of neg-
ative or high expression.
§Interaction variable states whether there is a difference in the treat-
ment response in relation to stromal -arrestin-1 status.their surroundings to create a permissive environment(the reactive tumor stroma) that supports tumor progres-
sion.40 The stromal compartment is made up of a number
of different secreted growth factors that disrupt normal
tissue homeostasis,41 which in turn activates distinct sub-
populations of stromal cells. An important feature of the
reactive tumor stroma is the carcinoma-associated fibro-
blasts (also known as activated fibroblasts). These cells
are mesenchymal-like and share characteristics with
smooth-muscle cells and fibroblasts.40 Carcinoma-asso-
ciated fibroblasts express markers such as -SMA, vi-
mentin, desmin, and fibroblast activation protein. Carci-
noma-associated fibroblasts have been observed in the
stroma of the majority of invasive breast cancers42,43 and
have been shown to stimulate tumor progression by se-
creting a wide range of different growth factors, hor-
mones, and cytokines targeting the tumor cells.44 We
speculate that a fraction of the -arrestin-1 expressing
cells of the stroma are carcinoma-associated fibroblasts,
which might be important for the clinical outcome of these
breast cancers. A positive correlation between -arres-
tin-1 and stromal -SMA implies that this actually is the
case, further supporting the emerging theory describing
the stroma as a determinant of tumor aggressiveness.
Altered expression of -arrestin-1 in the stroma might be
regulated by a paracrine signaling with the tumor cells
and so in turn emanate in a release of the growth sup-
pressing properties of the stroma on the tumor cells,
resulting in tumor cell proliferation, migration, and local
invasion. Moreover, a number of studies have reported
genetic alterations in the stroma to be associated with
clinicopathological parameters defining a more aggres-
sive tumor phenotype.38,45
Two other factors determining tumor aggressiveness
are the hypoxia markers HIF-1 and CAIX, which were
associated with high stromal expression of -arrestin-1 in
cohort II (HIF-1) and in cohort I (CAIX). Hypoxic tumors
often have a worse clinical outcome, compared with their
well-vascularized counterparts.46 Furthermore, both high
tumor cell and stromal expression of -arrestin-1 was
associated with ER (both cohorts) and PR (cohort II)
negativity, and with ERBB2 amplification (only tumor cell
expression in cohort II). ER and PR negativity and
ERBB2 amplification have been associated with the more
aggressive subtypes of breast cancer,47 and these pa-
tients are also less likely to respond to antihormonal
therapy.
The almost identical correspondence of the curves in
the survival analysis of cohort II patients exhibiting neg-
ative and high stromal -arrestin-1 expression is some-
what surprising (Figure 3B), but might be due to differ-
ences between the cohorts. In cohort I, all patients
included in the analysis received adjuvant therapy,
whereas the survival analysis of cohort II included un-
treated patients only, which might be a factor explaining
the differing results observed for stromal expression.
When including all patients or when analyzing treated
patients exclusively in cohort II, no significant differ-
ence was observed between patients showing different
expression levels of -arrestin-1 (data not shown). The
analysis criteria differed somewhat between the two
cohorts; however, because all patients in cohort I re-
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treatment could not be performed for these patients.
Furthermore, cohort I included both pre- and post-
menopausal patients, whereas cohort II included only
premenopausal patients, possibly contributing to the
inconsistent results. Nonetheless, it is difficult to draw
any conclusions about the underlying cause of the
differential effect of -arrestin-1 in pre- and postmeno-
pausal breast cancers.
Of note, patients with tumors displaying negative or
high stromal -arrestin-1 expression were the ones who
benefited from adjuvant treatment with tamoxifen, in con-
trast to those with low or moderately expressing tumors.
In the absence of tamoxifen, patients exhibiting low or
moderate -arrestin-1 expression did well, but in the
presence of tamoxifen these were the patients with the
highest risk of recurrence. No previous reports investigat-
ing the role of -arrestin-1 as a treatment predictive
marker in breast cancer exist, and further studies includ-
ing randomized patient cohorts would be required to
confirm our results. Moreover, functional studies are
needed to elucidate the mechanism by which expression
of this protein interferes with the action of tamoxifen and
confers resistance. Hattar et al48 reported that mammary
fibroblasts isolated from tamoxifen-treated rats exhibited
features of quiescent mammary microenvironment, with
decreased levels of fibronectin and reduced extracellular
matrix turnover. Thus, the stroma was functionally altered
by tamoxifen to inhibit tumor cell progression. Although
the underlying mechanism is poorly understood, a num-
ber of experimental studies in breast cancer cells have
shown that the therapeutic effects of antiestrogens are
mediated not only by targeting the epithelial cell compart-
ment, but also by targeting the stroma.49,50 Our results
further indicate that fibroblasts might be direct targets of
tamoxifen treatment, and might also be a source of ther-
apy resistance.
In recent years, the emerging role of the insulin-like
growth factor-1 receptor 1 (IGF-1R) in cancer progres-
sion has been recognized. IGF-1R is a receptor tyrosine
kinase, and signaling through this receptor is a central
mechanism in carcinogenesis, promoting tumor cell pro-
liferation and cell motility, as well as resistance to apop-
tosis.51 -Arrestin-1 has been implicated in IGF-1R sig-
naling in vitro, as a mediator of ubiquitination and
proteasomal degradation of the receptor.52 Furthermore,
silencing of -arrestin-1 in human melanoma cells results
in ablation of ERK stimulation by IGF-1R and prolonged
G1-phase of the cell cycle.53 These results imply a role
for -arrestin-1 in IGF-1R signaling mediated by ERK and
regulation of cell cycle progression.
We speculate that expression of -arrestin-1 might be
associated with the extent of IGF-1R signaling in the
patient cohorts; that is, patients with tumors of low -ar-
restin-1 expression would exhibit an increased IGF-1R
signaling, because of impaired receptor degradation.
This might explain the link between absence of stromal
-arrestin-1 and reduced RFS observed for patients in
cohort II. However, patients who presented with tumors
showing high expression of stromal -arrestin-1 were in
addition subject to a worse clinical outcome in both co-horts. The involvement of -arrestin-1 in IGF-1R-mediated
ERK signaling implies a link between high -arrestin-1
expression and more aggressive disease, because re-
duced protein levels results in decreased proliferation.
Moreover, the mechanisms promoting tumor progression
are likely to differ between tumor cells and cells of the
reactive tumor stroma. Hypothetically, altered IGF-1R sig-
naling in stromal cells is more critical in promoting tumor
aggressiveness than aberrant signaling via IGF-1R in
tumor cells in breast cancer. However, no data for IGF-1R
expression were available for our breast cancer cohorts,
and the mechanism underlying the observation that both
negative and high stromal -arrestin-1 expression was
associated with shorter RFS in cohort II is still elusive.
-Arrestin-1 is involved in various signaling pathways,
likely to be differentially regulated by this protein depend-
ing on the context. Notably, the results should be inter-
preted with caution because these two subgroups (neg-
ative and high expression) included fewer patients than
the remaining two subgroups of patients (low and mod-
erate expression). Nonetheless, the independent prog-
nostic value of stromal -arrestin-1 observed in both co-
horts implies that this is a potential novel biomarker in
breast cancer.
Loss of expression of caveolin-1 (Cav-1), a protein
involved in receptor-independent endocytosis exclu-
sively in the tumor-associated fibroblast compartment of
breast tumors, has been linked to early recurrence,
lymph node metastasis, and tamoxifen resistance.54,55
Caveolin-1 has been reported to enhance the interaction
between -arrestin-2 and the neurokinin-1 receptor in
clathrin-mediated endocytosis and signaling,56 suggest-
ing that regulation of Cav-1 might also affect the expres-
sion of -arrestin-1. Altered protein expression of -ar-
restin-1 in breast cancer stroma may be a result of lost
Cav-1 expression in stromal fibroblasts, resulting in
worse prognosis and tamoxifen insensitivity. Further-
more, high protein levels of stromal but not tumor cell
platelet-derived growth factor receptor  (PDGF-R-) has
been associated with unfavorable clinical characteristics
and reduced survival, particularly prominent in premeno-
pausal breast cancer patients, a finding that further high-
lights the importance of stromal markers in breast cancer
prognosis.57 PDGF-R- associates with G-protein-cou-
pled receptors in mammalian cells, and it is thus likely
that a relationship between this receptor and the -arres-
tins exists, potentially highlighting another link between
stromal -arrestin-1 expression and clinical outcome in
breast cancer.
Expression of tumor cell -arrestin-1 was inversely cor-
related with amplification of CCND1, a novel and intrigu-
ing discovery. The -arrestin-1 gene ARRB1 maps to
chromosomal locus 11q13 (11q13.4), the same region
that harbors CCND1. Amplification of CCND1 in cancer
has been reported to include several other genes located
in the 11q13 chromosomal region, including PAK116 and
cortactin (CTTN).58 In a previous study, we reported that
protein expression of PAK1 and cortactin was positively
correlated with CCND1 amplification in breast cancer,
suggesting a link between CCND1 amplification and am-
plification of PAK1 or CTTN.20 We speculate that a cor-
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protein expression would be positive, considering the
close proximity of the two genes. However, a deletion of
parts of the 11q chromosome has been reported, con-
current with the amplification event occurring at 11q13.19
In general, reports describe deletion of distal 11q, but
deletions in the 11q13 region have also been reported.59
Accordingly, ARRB1might be one of the genes deleted in
the amplification event frequently occurring at 11q13.
Supporting this finding is the positive correlation with the
CHEK1 protein, which is encoded by CHEK1 at 11q24 (ie,
distal 11q). We previously showed that protein expres-
sion of CHEK1 was inversely correlated with CCND1 am-
plification,20 indicating a loss of distal 11q concurrent
with the amplification of 11q13. The ARRB1 gene is lo-
cated between CCND1 and PAK1, demonstrating that
two amplicons of the 11q13 might be amplified without
the intervening chromosomal segment, as has been de-
scribed previously.18 Our present results indicate that,
instead of being coamplified with CCND1, the ARRB1
gene may be deleted. No relationship between CCND1
gene amplification and stromal -arrestin-1 expression
was found, implying that the tamoxifen resistance ob-
served for patients with tumors of low or moderate ex-
pression was not due to CCND1 amplification, which we
have previously reported to be associated with an ago-
nistic effect of tamoxifen.15
The present study demonstrates a previously unrecog-
nized finding, that the expression pattern of -arrestin-1
in tumor stroma exclusively predicts both clinical out-
come and response to tamoxifen in breast cancer. The
results highlight the emerging significance of stromal
characteristics as prognostic and predictive markers in
cancer. Nevertheless, much remains to be clarified in the
field of breast cancer and the tumor microenvironment,
and the role of the -arrestins in communication between
the cells that make up a solid tumor remains unknown.
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